Larimar Therapeutics has been granted a patent for methods, compositions, and kits to measure and modulate the activity of a frataxin (FXN) protein. The invention includes a method to measure enzymatic activity of FXN protein by detecting reactive oxygen species generation. GlobalData’s report on Larimar Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Larimar Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Larimar Therapeutics's grant share as of May 2024 was 21%. Grant share is based on the ratio of number of grants to total number of patents.
Measuring enzymatic activity of frataxin protein generating reactive oxygen species
A recently granted patent (Publication Number: US11988675B2) discloses a method for measuring the enzymatic activity of a Frataxin (FXN) protein by assessing the enzymatically catalyzed generation of reactive oxygen species (ROS). The method involves combining the FXN protein with a reducing agent and an ROS detector compound to create an assay mixture, measuring the ROS generated over time, and determining an enzymatic parameter associated with the ROS generating activity of the FXN protein. The pH range for combining the components is specified to be about 7.4 to about 9, with the option to include or exclude metal ions and iron ions in the assay mixture.
Furthermore, the patent claims cover various aspects of the method, including the addition of specific metal ions such as Mn2+, Fe3+, Zn2+, Cu2+, and Mg2+ into the assay mixture, the use of different compounds as reducing agents and ROS detector compounds, and the inclusion of FXN fusion proteins with cell-penetrating peptides. The method also allows for quality control testing on samples containing FXN proteins by measuring their activity using the described enzymatic assay. Overall, the patent provides a detailed and specific protocol for accurately measuring the enzymatic activity of FXN proteins, which could have implications for research and diagnostic applications related to conditions associated with Frataxin deficiency.
To know more about GlobalData’s detailed insights on Larimar Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
